Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative – Cardiometabolic Rare DiseaseKansas City, MORemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.
Taylor Strategy PartnersNewSpecialty Sales Representative - Cardiometabolic Rare Disease Taylor Strategy PartnersSpecialty Sales Representative - Cardiometabolic Rare DiseaseKansas City, MORemote$160,000–$180,000 / yearThis is a unique opportunity to play a meaningful role in the launch and growth of our cardiometabolic portfolio, including Plozasiran (siRNA targeting APOC3), developed for patients with rare and high-need cardiovascular conditions such as Familial Chylomicronemia Syndrome (FCS) and Severe Hypertriglyceridemia (SHTG). Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our clinical pipeline includes disease targets in the liver and lung with a promising pipeline of preclinical candidates.